A clinical isolate of Pseudomonas aeruginosu G48, became resistant during fluoroquinolone treatment giving rise to the posttherapy isolate, G49. To determine whether mutation in gyrA gave rise to fluoroquinolone resistance, G49 was transformed with a plasmid encoding gyrA (pNJR3-2); this reduced the MIC of fluoroquinolones for G49 two-fold. DNA sequencing of gyrA of G49 demonstrated a mutation at Thr-83, substituting with isoleucine. The outer membrane of G49 was shown to lack OprF, suggesting that loss of this protein may be involved in the multiple antibiotic resistance phenotype; however, when G49 was transformed with a plasmid encoding oprF (pRWS), expression of oprF was shown to have no effect upon the phenotype.
Introduction
Pseudomonas aeruginosa usually colonises individuals whose immune status is compromised by the nature of their disease or by prolonged chemotherapy [1, 2] . In the past, the vast majority of isolates of P. aeruginosa were generally sensitive to most antibiotics, but with increasing use of these agents a predominant percentage of more resistant strains have been recognised [l] . A resistant isolate of P. aeruginosa (strain G49) emerged during enoxacin therapy and is multiply resistant to antibiotics such as p-lactams, fluoroquinolones, chloramphenicol and was P. aeruginosu NCTC 10662 (Gl ). Plasmid pUCP19 is a derivative of the cloning vector pUC19 containing a stability factor which allows maintenance of the plasmid within Pseudomonas. Plasmid pUCP19 3.6 is pUCP19 containing the cloned P. aeruginosa wild-type gyrA gene obtained from J. Diver [4] . Plasmid pRW5 is pUCP19 containing the cloned oprF gene [S] . All strains were maintained on infusion agar slopes and at -20°C on Protect@ beads, except for G49 which was stored at 4°C due to its outer membrane defect.
Transformation of P. ueruginosu G48 and 649
with pUCPl9, pUCPI9 3.6 und pR W5
Plasmids were prepared using the Qiagen plasmid midi kit. Competent cells of G48 and G49 were prepared and transformed with the plasmids by electroporation [6] . Transformants were selected on LB agar containing carbenicillin at 500-1000 ug ml-'. The presence of plasmid in the transformants was verified by extracting plasmid DNA by the alkaline lysis method [7] , restriction digestion with Hind111 and agarose gel electrophoresis.
Antibiotics and determination of susceptibility
All antibiotics used in this study were supplied and used according to the manufacturers' instructions : carbenicillin, chloramphenicol, tetracycline, norfloxacin and nalidixic acid (Sigma); ciprofloxacin (Bayer); and enoxacin (Park-Davies Warner Lam- The minimum inhibitory concentrations (MIC) of each agent for all strains and transformants were determined in Isosensitest broth (Unipath) using a microtitre tray doubling dilution method, final inocula of 10" CFU ml-', and incubation at 37°C for 18 h. The MIC of each antibiotic was defined as the lowest concentration at which no growth was observed.
Outer membrane protein unulysis
Outer membranes were isolated from all strains and transformants as described previously [3] . Proteins were separated by electrophoresis on 14% SDS-PAGE gels and detected by Coomassie blue staining.
PCR and direct sequencing of oprF and gyrA
A 469 bp fragment of gyrA, covering the region analogous to the QRDR of E. coli gyrA, was amplified by the polymerase chain reaction (PCR) from P. ueruginosu Gl, G48 and G49, using primers pagyrA 1 (TGGGCAACGACTGGAACAAG) and pagyrA2 (ACTGCATCAGCTCATCGACG), as previously described [8] . PCR products were purified using Qiaquick spin columns (Qiagen) the nucleotide sequence determined directly using primer pagyrA1 and Sequenase 2.0 polymerase (US Biochemicals).
Similarly, a 511 bp PCR product containing the 5'-end and upstream promoter region of oprF was generated using primers paoprF1 (CAGATGCGACC-GAAACATAG) and 5'-biotinylated paoprF2 (CTGTCGCTGTTGATGTTGGT). PCR products were purified by binding to streptavidin-coated magnetic beads (Dynal) and the first 439 bp sequenced by solid-phase technology using primer paoprF1 and Sequenase 2.0. A 1052 bp PCR product encompassing the entire oprF gene was amplified using primers no. FPl (TTAGGCGTTGTCATCGGCTCG) and no. 3 (TTACTTGGCTTCGGCTTCTAC).
Results

Contribution of mutation in gyrA to Jluoroquinolone resistance
Sequencing of the amplified gyrA QRDR from G48 and G49 revealed a point mutation in G49 at codon 83 (ACC to ATC), resulting in the putative substitution of threonine for isoleucine. To determine the contribution of this mutation to the resistance phenotype, G48 and G49 were transformed with plasmid pUCP19.3.6, containing the wild-type P. aeruginosa gyrA gene cloned into pUCP19 [4] .
Transformation
of G49 with pUCP19 3.6 resulted in a reproducible 24fold decrease in the MICs of all 16 tested quinolones but did not alter the susceptibility to non-quinolone antibiotics (Table 1) . However, the G49 transformant still required higher concentrations of fluoroquinolone for inhibition than G49, suggesting that mutation in gyrA may be only partially responsible for the quinolone resistance phenotype of this isolate. Transformation of G48 with pUCP19 3.6 or either strain with pUCP19 had no effect on the susceptibility of the transformants to any antibiotic tested.
ing that OprF is not involved in the multiple antibiotic resistance phenotype.
Loss of OprF in G49 was demonstrated not to be due to deletion of the structural gene oprF by amplification of a PCR product encompassing the entire gene. Sequencing of the promoter and first 400 nucleotides of oprF from G48 and G49 revealed no changes between the two strains.
Discussion
Contribution of loss of OprF to multiple antibiotic resistance
Outer membrane profiles of G49 show several changes compared to G48, most noticeably complete loss of the outer membrane protein OprF [3] . To determine whether loss of this protein contributed to the multiple antibiotic resistance phenotype of G49, both G48 and G49 were transformed with plasmid pRW5, containing oprF cloned into pUCP19.
Expression of oprF in the G49 transformants was verified by SDS-PAGE analysis of outer membrane extracts (Fig. l) , however, no changes were observed in the MICs of any of the antibiotics tested, suggestIn the previous study conventional mechanisms of resistance to p-lactams and chloramphenicol, but not to fluoroquinolones, had been excluded [3] . In this study mutation in gyrA was shown to contribute, in part, to fluoroquinolone resistance, although complementation with wild-type gyrA did not restore susceptibility to pre-therapy levels. Therefore, another mechanism is required to account for the multiple antibiotic resistance in G49, including the non-gyrA mediated fluoroquinolone resistance. Despite the multiple antibiotic resistance phenotype there are several differences between G48 and G49, such as poor growth, brown pigmentation and outer membrane changes in the latter. Most noticeably, the outer membrane of G49 completely lacks OprF, and it was hypothesised whether this could be responsible for multiple antibiotic resistance. In a recent study, lack of OprF in a laboratory-generated multiple antibiotic resistant mutant was restored by transformation with cloned oprF [IS] and expression nulled the multiple antibiotic resistance phenotype; however, in the present study, cpression of OprF had no effect upon the susceptibility of G49. The lack of expression of OprF in G49 is perplexing, as G49 contains an intact structural gene for this protein, including the promoter region. No evidence exists to suggest that oprF is under regulatory control; however, it is possible that G49 contains a mutation in a genetic locus analogous to the marRAB operon in E.coli [9] affecting expression of several unlinked genes, including those giving rise to multiple antibiotic resistance, and also expression of oprF. Current work on G49 is focussing upon the role of antibiotic efflux [IO-131.
